Evidence map›Paper›PMID 42106798›Full record

ArticleCardio-oncology (London, England)2026

Real-world prevalence and outcome of elevated right ventricular systolic pressure in myelofibrosis.

Alexis Behne Sharma, Elicia Wang, Sruthi Selvakumar, Himara Koelmeyer, Sanath Shetty, Kinley Buckley, Qianxing Mo, Teagen Smith, Austin Chao, Carson Balen and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Alexis Behne SharmaDivision of Cardiovascular Medicine, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
Elicia WangMorsani College of Medicine, University of South Florida, Tampa, Florida, USA.
Sruthi SelvakumarDepartment of Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
Himara KoelmeyerDepartment of Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
Sanath ShettyDivision of Cardiovascular Medicine, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
Kinley BuckleyDepartment of Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
Qianxing MoDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
Teagen SmithResearch Methodology and Biostatistics Core, University of South Florida, Tampa, Florida, USA.
Austin ChaoMorsani College of Medicine, University of South Florida, Tampa, Florida, USA.
Carson BalenMorsani College of Medicine, University of South Florida, Tampa, Florida, USA.
Gowtam MannamMorsani College of Medicine, University of South Florida, Tampa, Florida, USA.
Jacob YudionoMorsani College of Medicine, University of South Florida, Tampa, Florida, USA.
Kyle LienMorsani College of Medicine, University of South Florida, Tampa, Florida, USA.
Sami KhatibMorsani College of Medicine, University of South Florida, Tampa, Florida, USA.
Varshith PaduchuriMorsani College of Medicine, University of South Florida, Tampa, Florida, USA.
Najla Al AliDepartment of Malignant Hematology, Moffitt Cancer Center & Research Institute, 12902 USF Magnolia Drive, Tampa, Florida, 33612, USA.
Jinming SongDepartment of Pathology, Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
Taiga NishihoriDepartment of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
Jeffrey E LancetDepartment of Malignant Hematology, Moffitt Cancer Center & Research Institute, 12902 USF Magnolia Drive, Tampa, Florida, 33612, USA.
Mohammed AlomarDivision of Cardiovascular Medicine, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
John L ClevelandDepartment of Tumor Microenvironment & Metastasis, Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
Andrew KuykendallDepartment of Malignant Hematology, Moffitt Cancer Center & Research Institute, 12902 USF Magnolia Drive, Tampa, Florida, 33612, USA.
Rami S KomrokjiDepartment of Malignant Hematology, Moffitt Cancer Center & Research Institute, 12902 USF Magnolia Drive, Tampa, Florida, 33612, USA.
Seongseok Yun *Department of Malignant Hematology, Moffitt Cancer Center & Research Institute, 12902 USF Magnolia Drive, Tampa, Florida, 33612, USA. Seongseok.yun@moffitt.org.
Dae Hyun Lee *Division of Cardiovascular Medicine, University of South Florida Morsani College of Medicine, Tampa, Florida, USA. Daehyun.lee@pennmedicine.upenn.edu.

Funding

American Heart Association 24CDA1271837
6 · The paper itself

Abstract

backgroundMyelofibrosis (MF) is a subgroup of Philadelphia chromosome-negative myeloproliferative neoplasms that are associated with an increased risk of cardiovascular disease, including pulmonary hypertension. Here we report the real-world prevalence, risk factors, and clinical outcomes of eRVSP in MF patients.

methodsA retrospective, single-center cohort study was conducted on 208 patients with MF that were diagnosed between 2013 and 2023. Elevated right ventricular systolic pressure (eRVSP) was defined as RVSP > 35 mmHg. Major adverse cardiac events (MACE) were defined as new-onset congestive heart failure, coronary artery disease requiring intervention, cerebrovascular events, or cardiovascular death after MF diagnosis. Univariate and multivariable Cox proportional hazard ratio regression model with eRVSP status as time-dependent covariate was used to estimate overall survival.

resultsEchocardiograms were performed in 208 MF patients, with RVSP estimates available in 156 patients (75%). eRVSP was present in 61 patients (39.1%). Patients with eRVSP were older (65 vs. 62 years, p = 0.053) and had higher rates of baseline hypertension (65.6% vs. 43.2%, p = 0.01), atrial fibrillation (16.4% vs. 4.2%, p = 0.02). MACE after diagnosis of MF occurred in 43 (20.7%) patients and was more frequent in eRVSP patients (36.1% vs. 15.8% p = 0.007), and this was predominantly driven by increased rates of new-onset congestive heart failure (27.9% vs. 8.4%, p = 0.003). In multivariable analysis, the presence of time-dependent eRVSP was associated with reduced survival (aHR: 4.41; 95%CI:2.84-6.85) after adjustment for clinically relevant covariates.

conclusionseRVSP was prevalent among MF patients undergoing echocardiogram and this was associated with increased cardiovascular morbidity, particularly HF. Furthermore, eRVSP was associated with inferior survival and underscores the need for targeted screening and management in MF patients with cardiovascular risk factors and diseases. Prospective studies with baseline cardiovascular assessment and echocardiograms in all MF patients will establish true prevalence and may further elucidate the morbidity and mortality implication of eRVSP in MF patients.

Identifiers

PMID42106798
PMCPMC13177858

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.